241 related articles for article (PubMed ID: 35154908)
1. Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.
Tapia-Galisteo A; Sánchez Rodríguez Í; Aguilar-Sopeña O; Harwood SL; Narbona J; Ferreras Gutierrez M; Navarro R; Martín-García L; Corbacho C; Compte M; Lacadena J; Blanco FJ; Chames P; Roda-Navarro P; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2022; 11(1):2034355. PubMed ID: 35154908
[TBL] [Abstract][Full Text] [Related]
2. Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
Mølgaard K; Harwood SL; Compte M; Merino N; Bonet J; Alvarez-Cienfuegos A; Mikkelsen K; Nuñez-Prado N; Alvarez-Mendez A; Sanz L; Blanco FJ; Alvarez-Vallina L
Cancer Immunol Immunother; 2018 Aug; 67(8):1251-1260. PubMed ID: 29869168
[TBL] [Abstract][Full Text] [Related]
3. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract][Full Text] [Related]
4. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement.
Chen L; Qian W; Pan F; Li D; Yu W; Tong L; Yang Y; Xu Q; Ding J; Dai R; Xian W; Zhu X; Ren P; Zhu H
Immunotherapy; 2024 Feb; 16(3):143-159. PubMed ID: 38126157
[TBL] [Abstract][Full Text] [Related]
5. Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression.
Ding Z; Sun S; Wang X; Yang X; Shi W; Huang X; Xie S; Mo F; Hou X; Liu A; Jiang X; Tang Z; Lu X
J Hematol Oncol; 2023 Nov; 16(1):115. PubMed ID: 38031188
[TBL] [Abstract][Full Text] [Related]
6. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
7. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy.
Frey G; Cugnetti APG; Liu H; Xing C; Wheeler C; Chang HW; Boyle WJ; Short JM
MAbs; 2024; 16(1):2322562. PubMed ID: 38445633
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.
Wang S; Peng L; Xu W; Zhou Y; Zhu Z; Kong Y; Leung S; Wang J; Yan X; Mi JQ
Front Med; 2022 Feb; 16(1):139-149. PubMed ID: 34463907
[TBL] [Abstract][Full Text] [Related]
9. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
10. Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.
Debelec-Butuner B; Quitt O; Schreiber S; Momburg F; Wisskirchen K; Protzer U
Front Immunol; 2022; 13():1029214. PubMed ID: 36405686
[TBL] [Abstract][Full Text] [Related]
11. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
12. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
13. Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells.
Kimura K; Kuwahara A; Suzuki S; Nakanishi T; Kumagai I; Asano R
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859608
[TBL] [Abstract][Full Text] [Related]
14. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.
Harwood SL; Alvarez-Cienfuegos A; Nuñez-Prado N; Compte M; Hernández-Pérez S; Merino N; Bonet J; Navarro R; Van Bergen En Henegouwen PMP; Lykkemark S; Mikkelsen K; Mølgaard K; Jabs F; Sanz L; Blanco FJ; Roda-Navarro P; Alvarez-Vallina L
Oncoimmunology; 2017; 7(1):e1377874. PubMed ID: 29296540
[TBL] [Abstract][Full Text] [Related]
15. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
16. [Preparation of CD33 targeted bispecific- and trispecific-T cell engagers and their cytotoxicity on leukemia cells].
Zhang T; Chen ML; Liu XY; He HZ; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):376-382. PubMed ID: 35680594
[No Abstract] [Full Text] [Related]
17. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
[TBL] [Abstract][Full Text] [Related]
18. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
Aschmoneit N; Kühl L; Seifert O; Kontermann RE
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
[TBL] [Abstract][Full Text] [Related]
19. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
[TBL] [Abstract][Full Text] [Related]
20. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.
Yin Y; Rodriguez JL; Li N; Thokala R; Nasrallah MP; Hu L; Zhang L; Zhang JV; Logun MT; Kainth D; Haddad L; Zhao Y; Wu T; Johns EX; Long Y; Liang H; Qi J; Zhang X; Binder ZA; Lin Z; O'Rourke DM
Mol Ther; 2022 Jul; 30(7):2537-2553. PubMed ID: 35570396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]